JID innovations : skin science from molecules to population health最新文献

{"title":"Association of Cardiovascular Disease in Patients with Mycosis Fungoides and Sézary Syndrome Compared to a Matched Control Cohort","authors":"Courtney M. Johnson ,&nbsp;Sai M. Talluru ,&nbsp;Bianka Bubic ,&nbsp;Michelle Colbert ,&nbsp;Priyanka Kumar ,&nbsp;Hua-ling Tsai ,&nbsp;Ravi Varadhan ,&nbsp;Sima Rozati","doi":"10.1016/j.xjidi.2023.100219","DOIUrl":"10.1016/j.xjidi.2023.100219","url":null,"abstract":"<div><p>Mycosis fungoides/Sézary syndrome (MF/SS) produces a low-grade chronic inflammatory state that may be associated with an increased risk of cardiovascular (CV) events, as seen in other chronic, systemic dermatologic diseases. To assess this association, a retrospective, cross-sectional study was designed in which 421 patients with a biopsy-proven diagnosis of MF/SS were compared with a control cohort of 4,210 age-, gender-, and race-matched patients randomly selected from the National Health and Nutritional Evaluation Survey database. The MF/SS cohort had a 14% prevalence of CV events, which was not statistically different from the control population’s prevalence of 13%. In the MF/SS cohort, a multivariable logistic regression model showed that older patients (OR = 1.05 for each year of age, 95% confidence interval = 1.02–1.07) and those diagnosed with hypertension (OR = 3.40, 95% confidence interval = 1.71–6.75) had a higher risk of a CV event (<em>P</em> &lt; 0.001). Risk factors such as gender, race, smoking, diabetes, and obesity were not significantly associated with CV events. Findings suggest that in the MF/SS population, advancing age and hypertension are risk factors for CV events, requiring clinical recognition and management. In addition, further research is needed to understand the complex interplay of how chronic inflammation in MF/SS impacts the immune development of CV disease.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"3 6","pages":"Article 100219"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000449/pdfft?md5=1823e23e49d646385c6e02392f357c7c&pid=1-s2.0-S2667026723000449-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42373997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo","authors":"Sarem Rashid ,&nbsp;Ivan Molotkov ,&nbsp;Nikolai Klebanov ,&nbsp;Michael Shaughnessy ,&nbsp;Mark J. Daly ,&nbsp;Mykyta Artomov ,&nbsp;Hensin Tsao","doi":"10.1016/j.xjidi.2023.100217","DOIUrl":"10.1016/j.xjidi.2023.100217","url":null,"abstract":"<div><p>Several observational studies have demonstrated a consistent pattern of decreased melanoma risk among patients with vitiligo. More recently, this finding has been supported by a suggested genetic relationship between the two entities, with certain variants significantly associated with an increased risk of melanoma, basal cell carcinoma, and squamous cell carcinoma but a decreased risk of vitiligo. We compared 48 associated variants from a recently published GWAS and identified three variants—located in the <em>TYR</em>, <em>MC1R-DEF8</em>, and <em>RALY-EIF2S</em><em>2-ASIP</em><em>-AHCY-ITCH</em> loci— that correlated with an increased risk for melanoma, basal cell carcinoma, and squamous cell carcinoma and a decreased risk for vitiligo. We then used results of skin cancers and vitiligo GWAS to compare the shared genetic properties between these two traits through an unbiased Mendelian randomization analysis. Our results suggest that the inverse genetic relationship between common skin cancers and vitiligo is broader than previously reported owing to the influence of shared genome-wide significant associations.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"3 6","pages":"Article 100217"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000425/pdfft?md5=8381d676045e8e78ae5bdadbf53fc0a2&pid=1-s2.0-S2667026723000425-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55189324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incident Comorbidity, Resource Use, and All-Cause Mortality Associated with Prurigo Nodularis: A United Kingdom Retrospective Database Analysis","authors":"Christopher Ll Morgan ,&nbsp;Melissa Thomas ,&nbsp;Benjamin R. Heywood ,&nbsp;Sonja Ständer ,&nbsp;Shawn G. Kwatra ,&nbsp;Zarif K. Jabbar-Lopez ,&nbsp;Christophe Piketty ,&nbsp;Sylvie Gabriel ,&nbsp;Jorge Puelles","doi":"10.1016/j.xjidi.2023.100233","DOIUrl":"https://doi.org/10.1016/j.xjidi.2023.100233","url":null,"abstract":"<div><p>We described comorbidity, resource utilization, and mortality for patients with prurigo nodularis (PN) using data from the Clinical Practice Research Datalink. Patients with incident PN (2008–2018) were selected and matched to controls. Of 2,416 patients with PN, 2,409 (99.7%) were matched to controls. Prevalence of atopic dermatitis (relative risk [RR] = 2.571; 95% confidence interval [CI] = 2.356–2.806), depression (RR = 1.705; 95% CI = 1.566–1.856), anxiety (RR = 1.540; 95% CI = 1.407–1.686), coronary heart disease (RR = 1.575; 95% CI = 1.388–1.787), chronic kidney disease (RR = 1.529; 95% CI = 1.329–1.759), and type 2 diabetes mellitus (RR = 1.836; 95% CI = 1.597–2.111) was significantly higher for patients with PN. Subsequent risk of atopic dermatitis (hazard ratio = 6.58; 95% CI = 5.17– 8.37), depression (hazard ratio = 1.61; 95% CI = 1.30–1.99), and coronary heart disease (hazard ratio = 1.37; 95% CI = 1.09–1.74) were significantly increased. Resource utilization was increased in all settings: incidence rate ratio = 1.48 (95% CI = 1.47–1.49) for primary care, incident rate ratio = 1.80 (95% CI = 1.75–1.85) for inpatients, incident rate ratio = 2.15 (95% CI = 2.13–2.18) for outpatients, and incidence rate ratio = 1.32 (95% CI = 1.27–1.36) for accident and emergency. Respective cost ratios were 1.78 (95% CI = 1.67–1.90), 1.52 (95% CI = 1.20–1.94), 2.34 (95% CI = 2.13–2.58), and 1.55 (95% CI = 1.33–1.80). Total primary and secondary healthcare costs were £2,531 versus £1,333, a cost ratio of 1.62 (95% CI = 1.36–1.94). The adjusted hazard ratio for mortality was 1.37 (95% CI = 1.14–1.66). Patients with PN had significantly increased rates of comorbidity, healthcare resources utilization, and mortality compared with matched controls.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"3 6","pages":"Article 100233"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000590/pdfft?md5=e6112ce8dfb42814b16c9e19cdb004fb&pid=1-s2.0-S2667026723000590-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92042334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Hypervascularization Treatment Using Photo-Mediated Ultrasound Therapy","authors":"Mingyang Wang ,&nbsp;Rohit Singh ,&nbsp;Wei Zhang ,&nbsp;Jeffrey S. Orringer ,&nbsp;Yannis M. Paulus ,&nbsp;Xinmai Yang ,&nbsp;Xueding Wang","doi":"10.1016/j.xjidi.2023.100237","DOIUrl":"https://doi.org/10.1016/j.xjidi.2023.100237","url":null,"abstract":"<div><p>Photo-mediated ultrasound therapy (PUT) is a cavitation-based, highly selective antivascular technique. In this study, the effectiveness and safety of PUT on cutaneous vascular malformation was examined through in vivo experiments in a clinically relevant chicken wattle model, whose microanatomy is similar to that of port-wine stain and other hypervascular dermal diseases in humans. Assessed by optical coherence tomography angiography, the blood vessel density in the chicken wattle decreased by 73.23% after one session of PUT treatment in which 0.707 J/cm² fluence laser pulses were applied concurrently with ultrasound bursts (n = 7, <em>P</em> &lt; .01). The effectiveness of removing blood vessels in the skin at depth up to 1 mm was further assessed by H&amp;E-stained histology at multiple time points, which included days 1, 3, 7, 14, and 21 after treatment. Additional immunohistochemical analyses with CD31, caspase-3, and Masson’s trichrome stains were performed on day 3 after treatment. The results show that the PUT-induced therapeutic effect was confined and specific to blood vessels only, whereas unwanted collateral damage in other skin tissues such as collagen was avoided. The findings from this study demonstrate that PUT can efficiently and safely remove hypervascular dermal capillaries using laser fluence at a level that is orders of magnitude smaller than that used in conventional laser treatment of vascular lesions, thus offering a safer alternative technique for clinical management of cutaneous vascular malformations.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"3 6","pages":"Article 100237"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000632/pdfft?md5=f35145bf2291046ee50ca712c9dda007&pid=1-s2.0-S2667026723000632-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92042335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy","authors":"Howa Yeung ,&nbsp;Krittin J. Supapannachart ,&nbsp;Sandy Francois ,&nbsp;Colin H. Adler ,&nbsp;Ragini R. Kudchadkar ,&nbsp;David H. Lawson ,&nbsp;Melinda L. Yushak ,&nbsp;Afreen I. Shariff ,&nbsp;Suephy C. Chen","doi":"10.1016/j.xjidi.2023.100232","DOIUrl":"https://doi.org/10.1016/j.xjidi.2023.100232","url":null,"abstract":"<div><p>Relationships between cutaneous adverse effects (CAEs) and noncutaneous adverse effects (NCAEs) of melanoma immunotherapy may help identify patterns tied to distinct immunologic pathways. The objective of this study was to determine the associations between CAEs and NCAEs among patients with stages III–IV melanoma receiving immunotherapy and who were enrolled in a prospective cohort. Electronic medical record data were abstracted from the first immunotherapy infusion until 1 year later. CAEs were rash or itch. NCAEs were symptoms and/or laboratory abnormalities documented as immunotherapy related. NCAE onset and time to NCAE were compared between participants with and without CAEs using ORs and Wilcoxon rank sum tests. Of 34 participants, 11 (32.4%) developed no adverse effects, 7 (20.1%) developed CAEs only, 3 (8.8%) developed NCAEs only, and 13 (38.2%) developed both CAEs and NCAEs. After adjustment for age, sex, and immunotherapy regimen, CAE was associated with higher odds of NCAE development (OR = 9.72; 95% confidence interval = 1.2–76.8). Median NCAE onset was 63 days in those with CAEs and 168 days in those without CAEs (<em>P</em> = 0.41). Limitations included a small sample size, and larger prospective studies should be performed to confirm findings. CAE was associated with NCAE development. Early identification and treatment of NCAEs may reduce symptom burden and hospitalizations associated with NCAEs.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"3 6","pages":"Article 100232"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000589/pdfft?md5=e896698892c386ecbc2b46484f97aa94&pid=1-s2.0-S2667026723000589-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92042336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VEXAS Syndrome—Diagnostic Clues for the Dermatologist and Gaps in Our Current Understanding: A Narrative Review","authors":"Lowell T. Nicholson ,&nbsp;Edward W. Cowen ,&nbsp;David Beck ,&nbsp;Marcela Ferrada ,&nbsp;Lauren M. Madigan","doi":"10.1016/j.xjidi.2023.100242","DOIUrl":"10.1016/j.xjidi.2023.100242","url":null,"abstract":"<div><p>Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome is a newly recognized, acquired autoinflammatory disorder with broad systemic implications and a poor global prognosis. Because cutaneous lesions are present in the majority of those affected, it is necessary that dermatologists are equipped to recognize this important disease. Through identification, there is a greater opportunity for disease stratification, surveillance for systemic involvement, and selection of the best available therapies. As our understanding of this disease develops, dermatologists should also play a role in addressing the knowledge gaps that exist.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 1","pages":"Article 100242"},"PeriodicalIF":0.0,"publicationDate":"2023-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000681/pdfft?md5=95274c94aa998995f1c212fcb06d538f&pid=1-s2.0-S2667026723000681-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136154002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antigen Protease Activity on Intact or Tape-Stripped Skin Induces Acute Itch and T Helper Sensitization Leading to Airway Eosinophilia in Mice","authors":"Toru Kimitsu ,&nbsp;Seiji Kamijo ,&nbsp;Tomoko Yoshimura ,&nbsp;Yurie Masutani ,&nbsp;Saya Shimizu ,&nbsp;Keiko Takada ,&nbsp;Punyada Suchiva ,&nbsp;Hideoki Ogawa ,&nbsp;Ko Okumura ,&nbsp;Shigaku Ikeda ,&nbsp;Toshiro Takai","doi":"10.1016/j.xjidi.2023.100239","DOIUrl":"10.1016/j.xjidi.2023.100239","url":null,"abstract":"<div><p>Respiratory allergen sources such as house dust mites frequently contain proteases. In this study, we demonstrated that the epicutaneous application of a model protease antigen, papain, onto intact or tape-stripped ear skin of mice induced acute scratching behaviors and T helper (Th)2, Th9, Th17/Th22, and/or Th1 sensitization in a protease activity–dependent manner. The protease activity of papain applied onto the skin was also essential for subsequent airway eosinophilia induced by an intranasal challenge with low-dose papain. With tape stripping, papain-treated mice showed barrier dysfunction, the accelerated onset of acute scratching behaviors, and attenuated Th17/Th22 sensitization. In contrast, the protease activity of inhaled papain partially or critically contributed to airway atopic march responses in mice sensitized through intact or tape-stripped skin, respectively. These results indicated that papain protease activity on epicutaneous application through intact skin or skin with mechanical barrier damage is critical to the sensitization phase responses, including acute itch and Th sensitization and progression to the airway atopic march, whereas dependency on the protease activity of inhaled papain in the atopic march differs by the condition of the sensitized skin area. This study suggests that exogenous protease-dependent epicutaneous mechanisms are a target for controlling allergic sensitization and progression to the atopic march.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 1","pages":"Article 100239"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000656/pdfft?md5=6370f05395eae17ed1e7f8b7fa967729&pid=1-s2.0-S2667026723000656-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134978000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Report and Proposals for Future Activity from the Inaugural Artificial Intelligence in Dermatology Symposium Held at the International Societies for Investigative Dermatology 2023 Meeting","authors":"Shannon Wongvibulsin ,&nbsp;Tobias Sangers ,&nbsp;Claire Clibborn ,&nbsp;Yu-Chuan (Jack) Li ,&nbsp;Nikhil Sharma ,&nbsp;John E.A. Common ,&nbsp;Nick J. Reynolds ,&nbsp;Reiko J. Tanaka","doi":"10.1016/j.xjidi.2023.100236","DOIUrl":"10.1016/j.xjidi.2023.100236","url":null,"abstract":"","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"4 1","pages":"Article 100236"},"PeriodicalIF":0.0,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667026723000620/pdfft?md5=7a0a5f252b4346cecfcb21bc6b4e2b33&pid=1-s2.0-S2667026723000620-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135433959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream","authors":"Michael D. Howell ,&nbsp;Fiona I. Kuo ,&nbsp;Beth Rumberger ,&nbsp;Erika Boarder ,&nbsp;Kang Sun ,&nbsp;Kathleen Butler ,&nbsp;John E. Harris ,&nbsp;Pearl Grimes ,&nbsp;David Rosmarin","doi":"10.1016/j.xjidi.2023.100230","DOIUrl":"10.1016/j.xjidi.2023.100230","url":null,"abstract":"<div><p>Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥50% improvement in facial Vitiligo Area Scoring Index scores by week 24 (group 1) and those who did not (group 2). Design: This was a posthoc analysis of a multicenter, randomized, double-blind, vehicle-controlled, phase 2 study in which screening was conducted between June 7, 2017 and March 21, 2018. Population: Patients aged between 18 and 75 years with vitiligo, including depigmentation affecting ≥0.5% of body surface area on the face and ≥3% of body surface area on nonfacial areas, were eligible. Intervention: Patients applied 1.5% ruxolitinib cream to lesions once or twice daily for 52 weeks. Main outcomes and measures: Patients were grouped by achievement of ≥50% improvement in facial Vitiligo Area Scoring Index at week 24. Proteomic analysis was performed on baseline serum samples. Results: Mean ± standard error facial Vitiligo Area Scoring Index in group 1 (n = 30) versus group 2 (n = 27) improved by 79.9 ± 4.0% versus 1.1 ± 7.3% and 91.9 ± 1.5% versus 25.1 ± 13.4% at weeks 24 and 52, respectively. Broad proteomic analysis revealed 76 proteins (of 1,104 tested) that were differentially expressed between groups 1 and 2 at baseline (<em>P</em> &lt; 0.05). Ten distinct proteins were upregulated in group 1; 64 were elevated in group 2. Conclusion: This analysis identified potential differences between patients who achieved ≥50% improvement in facial Vitiligo Area Scoring Index at 24 weeks and those who did not that require deeper scientific interrogation and may be important in stratifying therapeutic benefit for patients with vitiligo. Trial Registration: The original study was registered at <span>ClinicalTrials.gov</span><svg><path></path></svg>, NCT03099304.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"3 6","pages":"Article 100230"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/3a/main.PMC10568564.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the Angiotensin Pathway in the Treatment of Cutaneous Fibrosis: A Systematic Review","authors":"Trenton Greif ,&nbsp;Mouaz Alsawas ,&nbsp;Alexander T. Reid ,&nbsp;Vincent Liu ,&nbsp;Larry Prokop ,&nbsp;M. Hassan Murad ,&nbsp;Jennifer G. Powers","doi":"10.1016/j.xjidi.2023.100231","DOIUrl":"10.1016/j.xjidi.2023.100231","url":null,"abstract":"<div><p>Acting on the renin–angiotensin–aldosterone system, angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) are mechanisms of some of the most prescribed medications in the world. In addition to their routine use for the treatment of hypertension, such agents have gained attention for their influence on the angiotensin receptor pathway in fibrotic skin disorders, including scars and keloids. To evaluate the current level of evidence supporting the use of these agents, a systematic review related to ACE-Is/ARBs and cutaneous scarring was conducted. We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from database inception through January 26, 2022. Two independent reviewers identified eligible studies for inclusion and extracted data. Data were insufficient for meta-analysis and are presented narratively. Of 461 citations identified, seven studies were included (199 patients). The studies included two randomized clinical trials, one comparative observation study, and four case reports. All the included studies reported statistically significant improvement in cutaneous scarring in patients using ACE-Is/ARBs compared with that in those treated with placebo/control using various outcome measures such as scar size and scar scales. However, much of the literature on this subject to date is limited by study design.</p></div>","PeriodicalId":73548,"journal":{"name":"JID innovations : skin science from molecules to population health","volume":"3 6","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/ec/main.PMC10568560.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41241759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}